Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 21:35:12.
doi: 10.47176/mjiri.35.12. eCollection 2021.

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS

Alireza Mirzaei  1 , Seyed Adel Jahed  2 , Azade Amini Kadijani  3 , Mozhdeh Zabihiyeganeh  1
Affiliations

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS

Alireza Mirzaei et al. Med J Islam Repub Iran. .

Abstract

Background: There is no clear consensus regarding the potential of denosumab for increasing the risk of infection in patients who concurrently receive biologic disease-modifying anti-rheumatic drugs (bDMARDs). In this study, we compared the rate of infection in postmenopausal women with rheumatoid arthritis who received concurrent bDMARDs and denosumab with those who received bDMARDs alone. Methods: In a case-control study, postmenopausal patients with a confirmed diagnosis of rheumatoid arthritis who received concurrent bDMARDs and denosumab for at least one year were identified and included as the case group (n=40). A total of 44 age-matched postmenopausal rheumatoid arthritis women who received bDMARDs alone were included as the control group of the study. Using a chi-squared test, the incidence of bacterial or viral infections was extracted from the patients' profiles and compared between the two study groups. Statistical analyses were performed by SPSS for Windows, version 16 (Chicago, Illinois, USA). A p-value of fewer than 0.05 was regarded as significant. Results: The clinical and demographic characteristics of the patients of the two study groups were not significantly different. In total, four infections were recorded in the present series, two infections in each group. Accordingly, the rate of infection was 4.5% in the bDMARDs alone group and 5% in bDMARDs + denosumab group. This difference was not statistically significant (p=0.655, 95% CI: 0.121-6.742). Three out of four infections were herpes zoster infection. The other one was osteomyelitis of the first metatarsal bone, which occurred in the bDMARDs+denosumab group. None of the infections needed a hospitalization of IV antibiotics. Conclusion: The risk of infection is comparable between postmenopausal osteoporotic women with rheumatoid arthritis who receive bDMARDS alone and those who receive bDMARDS in combination with denosumab.

Keywords: Denosumab; Postmenopausal osteoporosis; Rheumatoid arthritis; bDMARDs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Heidari B, Hassanjani Roushan MR. Rheumatoid arthritis and osteoporosis. Caspian J Int Med. 2012;3(3):445–6. - PMC - PubMed
    1. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522–30. - PubMed
    1. Ji M-X, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Translat Med. 2015;1(1):9. - PMC - PubMed
    1. Mirzaei A, Jahed SA, Nojomi M, Rajaei A, Zabihiyeganeh M. A study of the value of trabecular bone score in fracture risk assessment of postmenopausal women. Taiwan J Obstet Gynecol. 2018;57(3):389–93. - PubMed
    1. Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM. et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess. 2001;28:1–2. - PMC - PubMed

LinkOut - more resources